Couple of thoughts about this.
- Is this the med onc equivalent of the rad onc supervision rule? As precision oncology moves away from cytotoxic agents, we will be getting more systemic therapies that are either pills or subq injections like this. What happens to reimbursement from infusion centers if their volumes go down?
- Will this make it easier for rad oncs to prescribe systemic agents in the future? Some already do for ADT. If cetuximab becomes subq, its not a huge leap to think about a rad onc prescribing at some point